Loss of Exclusivity (LOE): Marketing and Media Scenario Planning
How brands plan marketing around loss of exclusivity: timing scenarios, erosion assumptions, what to cut first, what to protect, and measurement.
The short answer
Loss of exclusivity (LOE) is when patents and regulatory exclusivity end and generics or biosimilars can enter. LOE planning builds scenarios for entry timing and erosion speed, then decides how to step down broad media, protect loyal patients and key HCP relationships, adjust support programs, and redeploy budget, so spend falls with value instead of continuing on autopilot.
Every brand reaches LOE. Some handle it well, cutting spend in step with value and protecting what can be protected. Others keep spending at full rate until the month generics arrive, then cut everything at once. Scenario planning is how you avoid the second outcome.
Why LOE is uncertain
- Timing. Patent litigation, settlements, and regulatory steps can move entry dates.
- Number of entrants. One generic erodes differently from many.
- Product type. Small molecules typically lose volume quickly through pharmacy substitution. Biologics facing biosimilars often erode more slowly, depending on interchangeability and payer action.
- Payer and pharmacy behavior. Formulary changes can accelerate or delay erosion.
Build three scenarios
| Scenario | Entry timing | Erosion | Marketing implication |
|---|---|---|---|
| Early, fast | Earlier than expected; many entrants | Steep | Cut broad media early; focus on support programs |
| Base | Expected date | Typical for product type | Planned step-down |
| Late, slow | Delayed entry or slow uptake | Gradual | Maintain targeted activity longer |
For each, set trigger events, such as a court decision or a first approval of a generic, that tell you which scenario you are in.
What to step down first
- Broad awareness media. TV, CTV, and wide programmatic usually stop first. Awareness has little value when substitution decides the product dispensed.
- New-patient acquisition tactics. Lower return as generics capture new starts.
- Low-tier HCP coverage. Concentrate on HCPs with the most loyal patients.
What to protect
- Patient support and adherence programs, especially for complex therapies, where they affect outcomes and loyalty.
- Key HCP relationships in specialties where brand loyalty persists.
- Devices or formulations that differ from generic versions, if any.
Any messaging about the brand versus generics must follow FDA rules and avoid misleading claims about substitutes.
Redeploying budget
LOE frees budget. Plan where it goes: newer brands, pipeline launches, or portfolio programs. Decide this before LOE so the money does not disappear into general cuts.
Measurement around LOE
- Track erosion weekly against each scenario.
- Measure retention among patients in support programs versus those not enrolled.
- Use holdouts if you keep any media running, to check it still adds value. See scale, hold, or stop a pilot.
Timeline
| Time to expected LOE | Action |
|---|---|
| 24 months | Build scenarios and triggers |
| 12 months | Decide step-down plan and protected programs |
| 6 months | Begin reducing broad media in base case |
| 0 to 6 months after | Monitor erosion, adjust, redeploy budget |
Common mistakes
- Keeping full media weight until the entry date.
- Cutting patient support along with media.
- One forecast with no scenarios or triggers.
- No plan for the freed budget.
Practical takeaway
If your brand is within two years of LOE, write the trigger events that would move you between scenarios, and the media line items you would cut first in each. That one page will save more money than any optimization in the final year.
Frequently asked questions
What does LOE mean in pharma?
Loss of exclusivity: the point when a brand's patents and regulatory exclusivities end and generic or biosimilar competitors can launch.
Should brands stop marketing at LOE?
Usually most broad promotion stops or drops sharply, because generic substitution limits the return. Some brands keep targeted programs for loyal patients, support services, or specific segments.
Why do biosimilars erode differently from small-molecule generics?
Biosimilar uptake depends on interchangeability, payer decisions, and physician comfort, so erosion is often slower and less predictable than for small-molecule generics.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.